 |
|
|
|
|
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Resolve Therapeutics, LLC
| | | | | Phone: | (208) 727-7010 | | Year Established: | 2010 | | Employees: | 6 | | Main Contact: | James Posada, Ph.D., MBA, CEO & Co-Founder | | | | Other Contacts: | Peter Kiener, D. Phil, Chairman
Chris Gabel, Ph.D., CSO
| | | | Company Description | | Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of RSLV-132, its novel targeted biologic therapy. RSLV-132 represents a new approach to inhibiting the production of interferon-alpha at a proximal step in the inflammatory cascade. A multitude of evidence points to interferon-alpha as a critical mediator of the inflammation present in lupus patients. Development efforts in this field are greatly enhanced by the recent clinical validation of a biomarker called the “interferon signature” which tracks the activation level of the interferon pathway in lupus patients. The interferon signature provides a valuable pharmacodynamic endpoint which greatly enhances the early clinical evaluation of drugs acting to inhibit the interferon pathway. RSLV-132 is currently in advanced preclinical development, and Resolve expects to begin human clinical studies with this compound in the near future. | |
|
|
|
|
|
|
|
